Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen

J Acquir Immune Defic Syndr. 2001 Apr 1;26(4):389-90. doi: 10.1097/00126334-200104010-00018.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • Female
  • HIV Infections / blood
  • HIV Infections / complications*
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / complications*
  • Hyperlipidemias / drug therapy*
  • Male
  • Oxazines / administration & dosage
  • Oxazines / therapeutic use*
  • Retrospective Studies
  • Reverse Transcriptase Inhibitors / administration & dosage
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Ritonavir / administration & dosage
  • Ritonavir / adverse effects
  • Ritonavir / therapeutic use
  • Triglycerides / blood

Substances

  • Alkynes
  • Benzoxazines
  • Cyclopropanes
  • HIV Protease Inhibitors
  • Oxazines
  • Reverse Transcriptase Inhibitors
  • Triglycerides
  • efavirenz
  • Ritonavir